208,277 Ironwood Pharmaceuticals, Inc. $IRWD Shares Purchased by CWA Asset Management Group LLCDefense World · 5 days ago
Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive OfficerBusiness Wire · Oct 16, 2026
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Stock Rated “Moderate Buy” by Sell-Side BrokeragesDefense World · Oct 13, 2026
Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3?Zacks Investment Research · Oct 7, 2026
Ironwood Pharmaceuticals: The Stock Is A Call On The Second Apraglutide Trial - BuySeeking Alpha · Oct 7, 2026
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?Zacks Investment Research · Sep 30, 2026Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | $0.32 | $0.31 | Miss |
| May 7, 2026 | $0.07 | $0.24 | Beat |
| Feb 25, 2026 | $0.02 | -$0.01 | Miss |
| Nov 10, 2025 | $0.09 | $0.24 | Beat |
| Aug 7, 2025 | -$0.02 | $0.14 | Beat |
| May 7, 2025 | -$0.05 | -$0.23 | Miss |